Shanghai Henlius Biotech, Inc.
2696
주식 순위
#4380
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise,... Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
주가
$6.57
마지막 동기화: 2026-10-16
시가총액
$3.58B
변동 (1일)
2.39%
변동 (1년)
-30.10%
국가
CN
거래 Shanghai Henlius Biotech, Inc. (2696)
카테고리
Healthcare
Shanghai Henlius Biotech, Inc. (2696)의 영업이익률
October 2026 기준 영업이익률 TTM: 12.06%
Shanghai Henlius Biotech, Inc.의 최신 재무 보고서와 주가에 따르면 현재 영업이익률 (TTM)은 12.06%입니다. 2023년 말 기준 영업이익률은 11.71%였습니다.
Shanghai Henlius Biotech, Inc.의 영업이익률 기록 (2017 ~ 2026)
매년 말 영업이익률
| 연도 | 영업이익률 | 변화 |
|---|---|---|
| 2026 (TTM) | 12.06% | -26.51% |
| 2024 | 16.41% | 40.14% |
| 2023 | 11.71% | -159.90% |
| 2022 | -19.55% | -50.56% |
| 2021 | -39.54% | -74.88% |
| 2020 | -157.42% | -82.57% |
| 2019 | -903.13% | -85.32% |
| 2018 | -6,151.77% | 541.95% |
| 2017 | -958.30% | 0.00% |
유사 기업 또는 경쟁사의 영업이익률
| 회사 | 영업이익률 | 영업이익률 차이 | 국가 |
|---|---|---|---|
| 38.59% | -96.80% |
US
|
|
| -149.01% | -112.36% |
US
|
|
| 25.57% | -97.88% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -97.61% |
NL
|
회사의 영업이익률이란?
영업이익률은 회사의 수익성을 평가하는 핵심 지표입니다. 높은 영업이익률은 일반적으로 긍정적으로 간주되며, 이는 회사가 제품이나 서비스를 생산 비용보다 훨씬 높은 가격에 판매할 수 있음을 보여줍니다. 영업이익률은 회사의 수익을 매출로 나누어 계산합니다.